NNVC · Nanoviricides, Inc.
$1.12
-0.03 (-2.61%)
At close · Sep 4
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management believes that the Company’s cash and cash equivalents balance of approximately $3.2 million, and the Company’s existing resources, including availability under its $3 million line of credit will not be sufficient to fund the Company’s planned operations and expenditures for at least 12 months from the date of the filing of this Form 10-Q. As a result, substantial doubt exists about the Company’s ability to continue as a going concern.”View the 10-Q filed May 15, 2026
Market Cap
$24.89M
Shares
21.65M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Meeta Vyas | CFO | $133,922 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Meeta Vyas | CFO | $133,507 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Meeta Vyas | CFO | $137,348 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Meeta Vyas | CFO | $147,729 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Meeta Vyas | CFO | $154,548 |
| Irach Taraporewala | Ex-CEO | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Anil Diwan | President, Director | $589,038 |
| Meeta Vyas | CFO | $150,469 |
| Irach Taraporewala | Ex-CEO | — |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Anil Diwan | President, Director | $589,038 |
| Irach Taraporewala | Ex-CEO | $228,703 |
| Former CEO | — | $228,703 |
| Meeta Vyas | CFO | $154,088 |
Key facts
CIK
1379006
CUSIP
630087302
13F (30d)
37 filings
37 filers
Visit website
Investor relations